Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
Subanalysis of Patients with Secondary Acute Myeloid Leukemia (sAML) with Refractory Anemia with Excess of Blasts in Transformation (RAEB-T) Enrolled in a Phase 3 Study of CPX-351 Versus Conventional 7+3 Cytarabine and Daunorubicin Lin, T. L., Uy, G. L., Wieduwilt, M. J., Newell, L. F., Stuart, R. K., Medeiros, B. C., Schiller, G. J., Rubenstein, S., Stock, W., Warlick, E., Foster, M., Bixby, D. L., Podoltsev, N., An, Q., Faderl, S., Louie, A. C., Lancet, J. E. ELSEVIER SCIENCE INC. 2018: S228–S229
View details for Web of Science ID 000425476000315